Arcadia Biosciences (NASDAQ:RKDA) Now Covered by StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research note issued on Sunday. The firm set a “sell” rating on the basic materials company’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Arcadia Biosciences in a research report on Wednesday, August 21st.

Arcadia Biosciences Trading Up 3.9 %

Arcadia Biosciences stock opened at $2.90 on Friday. Arcadia Biosciences has a 1-year low of $1.85 and a 1-year high of $3.93. The firm has a market cap of $3.94 million, a P/E ratio of -0.56 and a beta of 1.34. The firm has a 50-day moving average of $2.81 and a 200-day moving average of $2.70.

Arcadia Biosciences (NASDAQ:RKDA) last announced its earnings results on Tuesday, August 13th. The basic materials company reported $0.78 EPS for the quarter, missing analysts’ consensus estimates of $1.27 by ($0.49). Arcadia Biosciences had a negative net margin of 127.29% and a negative return on equity of 57.51%. The business had revenue of $1.31 million for the quarter, compared to the consensus estimate of $0.95 million. During the same quarter in the prior year, the company earned ($2.64) EPS. Research analysts forecast that Arcadia Biosciences will post -1.7 earnings per share for the current fiscal year.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.